EXACT SCIENCES CORP Forms 3, 4 and 5: Restricted Stock Units and Performance Rights
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 40 rows in 2024. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2024-08-05: Reporting owner Baranick Brian; Form 4; Security Restricted Stock Units; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2024-08-05: Reporting owner Baranick Brian; Form 4; Security Restricted Stock Units; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2024-08-05: Reporting owner ORVILLE JACOB A; Form 4; Security Restricted Stock Units; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2024-06-13: Reporting owner Barber Michael J; Form 4; Security Deferred Stock Units; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2024-08-05 | Baranick Brian Officer (EVP, GM, Precision Oncology) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,712 0 owned after | $0.00 | 2024-08-06 | |
| 2024-08-05 | Baranick Brian Officer (EVP, GM, Precision Oncology) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +21,401 21,401 owned after | $0.00 | 2024-08-06 | |
| 2024-08-05 | ORVILLE JACOB A Officer (EVP, GM, Screening) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +21,401 21,401 owned after | $0.00 | 2024-08-06 | |
| 2024-06-13 | Barber Michael J Director | 4 | Deferred Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,422 7,422 owned after | $0.00 | 2024-06-17 | |
| 2024-05-20 holding as of filing | Bloomer Aaron Officer (EVP, Chief Financial Officer) | 3 | Restricted Stock Units Derivative · Direct | Holding | no price filed | 2024-05-20 | ||
| 2024-05-20 holding as of filing | Bloomer Aaron Officer (EVP, Chief Financial Officer) | 3 | Restricted Stock Units Derivative · Direct | Holding | no price filed | 2024-05-20 | ||
| 2024-02-29 | ORVILLE JACOB A Officer (General Manager, Screening) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,724 14,175 owned after | $0.00 | 2024-03-04 | |
| 2024-02-29 | Herriott James Officer (General Counsel) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,890 5,670 owned after | $0.00 | 2024-03-04 | |
| 2024-02-29 | Elliott Jeffrey Thomas Officer (Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,291 15,876 owned after | $0.00 | 2024-03-04 | |
| 2024-02-29 | Cunningham Everett Officer (Chief Commercial Officer) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,291 15,876 owned after | $0.00 | 2024-03-04 | |
| 2024-02-29 | Conroy Kevin T Director, Officer (President and CEO) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −18,143 54,429 owned after | $0.00 | 2024-03-04 | |
| 2024-02-29 | Condella Sarah Officer (EVP, Human Resources) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,779 11,340 owned after | $0.00 | 2024-03-04 | |
| 2024-02-29 | Baranick Brian Officer (Gen. Mgr., Precision Oncology) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,724 14,175 owned after | $0.00 | 2024-03-04 | |
| 2024-02-26 | ORVILLE JACOB A Officer (General Manager, Screening) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,954 7,909 owned after | $0.00 | 2024-02-28 | |
| 2024-02-26 | ORVILLE JACOB A Officer (General Manager, Screening) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +19,793 19,793 owned after | $0.00 | 2024-02-28 | |
| 2024-02-26 | Herriott James Officer (General Counsel) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,648 3,295 owned after | $0.00 | 2024-02-28 | |
| 2024-02-26 | Herriott James Officer (General Counsel) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,500 9,500 owned after | $0.00 | 2024-02-28 | |
| 2024-02-26 | Cunningham Everett Officer (Chief Commercial Officer) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,678 15,356 owned after | $0.00 | 2024-02-28 | |
| 2024-02-26 | Cunningham Everett Officer (Chief Commercial Officer) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +31,668 31,668 owned after | $0.00 | 2024-02-28 | |
| 2024-02-26 | Elliott Jeffrey Thomas Officer (Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,701 11,401 owned after | $0.00 | 2024-02-28 | |
| 2024-02-26 | Elliott Jeffrey Thomas Officer (Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,750 4,750 owned after | $0.00 | 2024-02-28 | |
| 2024-02-26 | Conroy Kevin T Director, Officer (President and CEO) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,181 26,361 owned after | $0.00 | 2024-02-28 | |
| 2024-02-26 | Conroy Kevin T Director, Officer (President and CEO) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +88,671 88,671 owned after | $0.00 | 2024-02-28 | |
| 2024-02-26 | Condella Sarah Officer (EVP, Human Resources) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,954 7,909 owned after | $0.00 | 2024-02-28 | |
| 2024-02-26 | Condella Sarah Officer (EVP, Human Resources) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,834 15,834 owned after | $0.00 | 2024-02-28 | |
| 2024-02-26 | Baranick Brian Officer (Gen. Mgr., Precision Oncology) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,954 7,909 owned after | $0.00 | 2024-02-28 | |
| 2024-02-26 | Baranick Brian Officer (Gen. Mgr., Precision Oncology) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +19,793 19,793 owned after | $0.00 | 2024-02-28 | |
| 2024-02-20 | ORVILLE JACOB A Officer (General Manager, Screening) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,248 0 owned after | $0.00 | 2024-02-22 | |
| 2024-02-20 | Herriott James Officer (General Counsel) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −864 0 owned after | $0.00 | 2024-02-22 | |
| 2024-02-20 | Elliott Jeffrey Thomas Officer (Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,112 0 owned after | $0.00 | 2024-02-22 | |
| 2024-02-20 | COWARD D SCOTT Director | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,248 0 owned after | $0.00 | 2024-02-22 | |
| 2024-02-20 | Conroy Kevin T Director, Officer (President and CEO) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,374 0 owned after | $0.00 | 2024-02-22 | |
| 2024-02-20 | Condella Sarah Officer (EVP, Human Resources) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,248 0 owned after | $0.00 | 2024-02-22 | |
| 2024-02-20 | Baranick Brian Officer (Gen. Mgr., Precision Oncology) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,729 0 owned after | $0.00 | 2024-02-22 | |
| 2024-02-14 | ORVILLE JACOB A Officer (General Manager, Screening) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,031 0 owned after | $0.00 | 2024-02-16 | |
| 2024-02-14 | Herriott James Officer (General Counsel) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −883 0 owned after | $0.00 | 2024-02-16 | |
| 2024-02-14 | Elliott Jeffrey Thomas Officer (Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,972 0 owned after | $0.00 | 2024-02-16 | |
| 2024-02-14 | COWARD D SCOTT Director | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,972 0 owned after | $0.00 | 2024-02-16 | |
| 2024-02-14 | Conroy Kevin T Director, Officer (President and CEO) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −31,133 0 owned after | $0.00 | 2024-02-16 | |
| 2024-02-14 | Condella Sarah Officer (EVP, Human Resources) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,031 0 owned after | $0.00 | 2024-02-16 |